A 664-patient, 63-site trial presented at the European Stroke Organisation Conference showed use of W.L. Gore & Associates' Cardioform septal occluder or its earlier-generation Helex septal occluder plus antiplatelet drugs in patients with a patent foramen ovale and a history of stroke led to a 76.6% reduction in recurrent ischemic stroke compared with antiplatelet therapy alone. Results of the trial are expected to support the company's FDA application for a patent foramen ovale indication for the Cardioform device by year's end.
Trial shows positive results for W.L. Gore's septal occluders
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.